Abortion pill ruling could be "catastrophic" for new drug development
Supreme Court,Abortion,Abortion Pills,Healthcare,Women's Issues,Pharmaceuticals
The Supreme Court today will hear a challenge to the FDA's approval of mifepristone, a medicine used to help induce abortions.
Why it matters: Were SCOTUS to rule in favor of mifepristone's opponents, it could chill future biotech investment for almost every medical indication.
Zoom out: The core question in the case is over whether the FDA has sole discretion to determine a drug's efficacy and safety, or if courts also can play a role.
The former is how biotech has traditionally operated. It's not cheap, but at least the process is understood and uniform.
Introducing the possibility of litigation creates costly new variables, to the point that investors may no longer think the reward is worth the risk. Particularly given that the timeline for challenging FDA decisions could be boundless.
Between the lines: Imagine court cases on everything from vaccines to Viagra to Ozempic. Or drugs whose development included the use of embryonic stem cells.
Related Coverage
AllSides Picks
Headline Roundup
NSA Confirms Temporary Network Disruption Amid Other Recent Outages
November 17th, 2026
Headline Roundup
US Loses Measles Elimination Status After 26 Years
November 17th, 2026
Recommended Reading
When Democrats Have To Decide
Dan Schnur
November 16th, 2026
The Insight
Is America’s Homelessness Crisis Improving?
AllSides Staff
November 13th, 2026
More News about Supreme Court
News from the Left
News from the Center
News from the Right
CNBC